{"node": "root", "content": "Patient with Suspected CHRONIC MYELOGENOUS LEUKEMIA", "children": [{"node": "A", "content": "History, Physical examination", "children": []}, {"node": "B", "content": "CBC", "children": []}, {"node": "C", "content": "Bone Marrow Biopsy/Aspiration, Cytogenetics, FISH, Quantitative PCR for bcr-abl", "children": [{"node": "Diagnosis established", "content": "Consider patient age, Assess treatment-related mortality with allogeneic stem cell transplant", "children": [{"node": "D", "content": "Chronic phase", "children": [{"node": "Histocompatible siblings", "content": "Therapy: Imatinib 400 mg PO qd", "children": [{"node": "F", "content": "Assess response to imatinib: CHR by 3 mo, MCGR by 9-12 mo", "children": [{"node": "Yes", "content": "Continue Imatinib with Quarterly Monitoring", "children": []}, {"node": "No", "content": "Increase Imatinib to 600-800 mg PO qd", "children": []}]}]}, {"node": "No histocompatible siblings", "content": null, "children": []}]}, {"node": "E", "content": "Accelerated phase or blast transformation", "children": [{"node": "Imatinib 800 mg PO qd", "content": null, "children": []}, {"node": "G", "content": "Allogeneic Stem Cell Transplantation", "children": []}]}]}]}]}